Therapix

63 articles with Therapix

• SciSparc to Conduct a Phase IIa Clinical Trial in Alzheimer's Patients Using the Company's Proprietary Cannabinoid-Based Treatment

  2/17/2021

  The Israeli Medical Center for Alzheimer's will evaluate the safety, tolerability and efficacy of SCI-110 in patients with Alzheimer's disease and agitation

• Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada

  1/5/2021

  Therapix Biosciences Ltd. (OTCQB: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced it has entered a non-binding letter of intent with Cy

• Therapix Biosciences Announces Replacement of its Board of Directors

  8/21/2020

  Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today the replacement of its board of directors. The Company's new six-member board of directors will include Itschak Shrem , Amitay Weiss , Moshe

• Therapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court

  7/9/2020

  Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that its American Depositary Shares ("ADSs") will now trade under the OTC Pink ticker symbol "TRPXY." The Company also announced the removal by an

• Therapix Biosciences Receives Notice of Delisting and Injunction from Israeli Court

  7/1/2020

  Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today receipt of Notice of Delisting and Injunction from Israeli Court. Notice of Delisting On June 30, 2020 , Therapix Biosci

• Therapix Biosciences Raises $2.6 Million in Private Placement

  6/29/2020

  Therapix Biosciences Ltd. (" Therapix " or the " Company ") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced that it has entered into definitive agreements with several accredited and institutional investors providing for the issuance of a

• Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication

  5/19/2020

  Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments announced today that it has closed a

• Therapix Biosciences Announces Pricing of $1.25 Million Public Offering

  4/1/2020

  Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced the pricing of a public offering for the issuance of an aggregate of 4,166,668 units, each consisting of (i) one pre-funded warrant t

• Therapix Biosciences Ltd. Announces Shareholder Conference Call

  3/25/2020

  Therapix Biosciences Ltd. announced today that the Company will host a conference call on Wednesday, April 22, 2020, at 4:30 PM EDT. ET 

• Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program

  11/13/2019

  Study meets its primary endpoint

• Therapix Biosciences Announces Canadian Product License Issuance for TheraPEA (CannAmide™), a Non-Opiate Based Pain Management Supplement

  7/31/2019

  This license is issued by Health Canada under the authority of the Natural Health Products Regulations.

• Therapix Biosciences Signs LOI to Merge With Destiny Biosciences Global Corp. in a Stock for Stock Transaction Valuing Therapix at US$48 Million

  7/23/2019

  The transaction will create a combined company that focuses on Therapix's proprietary IP and related technology, and assets pertaining to all clinical stage pharmaceutical applications and Destiny's genomics-based breeding techniques and development capabilities.

• Therapix Biosciences Announces First Quarter 2019 Condensed Financial Data

  7/5/2019

  Therapix Biosciences Ltd., a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced condensed consolidated financial data for the first quarter of 2019

• Therapix Biosciences Announces Interim Results of Phase IIa Study at Assuta Medical Center for Obstructive Sleep Apnea Program

  6/18/2019

  The study is being conducted under the leadership of Professor Yaron Dagan, head of the Sleep Medicine Institute at Assuta, and Principal Investigator, Dr. Lilach Kemer.

• Therapix Biosciences Announces Pricing of $2.25 Million Registered Direct Offering

  3/28/2019

  Therapix Biosciences Ltd. announced that it has entered into definitive agreements with several accredited and institutional investors providing for the issuance of an aggregate of 642,853 American depositary shares at a purchase price of $3.50 per ADS in a registered direct offering.

• Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor

  3/19/2019

  Therapix Biosciences Ltd. announced that the Company has appointed Ambassador Ron Prosor as a global growth strategy and international business development advisor.

• FSD Pharma Responds to Therapix Termination of Binding LOI

  12/21/2018

  FSD Pharma Inc. in response to Therapix Biosciences’ termination of the company’s binding letter of intent to be acquired by FSD Pharma, Dr. Raza Bokhari, Executive Co-Chairman of the Board of FSD Pharma, released the following statement

• Therapix Biosciences Issues $1,500,000 Convertible Debenture

  11/27/2018

  Therapix. ("Therapix" or the "Company") (NASDAQ: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announces that the Company has entered into a securities purchase agreement in a private placement with YA II PN Ltd. (the "Investor"), a fund managed by Yorkville Advisors Global, for up to $2.5 million in principal amount of unsecured convertible debentures (the "Debentures").

• Therapix Biosciences Signs Binding LOI to be Acquired by FSD Pharma for $48 Million, to Create Medical Cannabis Industry Innovator

  10/24/2018

  The Transaction focuses on Therapix proprietary IP and related technology, and assets pertaining to all clinical stage pharmaceutical assets applications, excluding certain pain assets, such as the US based pain clinics.

• Therapix Biosciences Announces Positive Data From Recent Pre-clinical Studies for its Drug Candidate THX-160 for Treatment of Pain

  7/17/2018

  This innovative CB2 receptor agonist was synthesized by Raphael Mechoulam, Ph.D.